LEADER 02391cam 2200313 a 45 0
001 306132
003 TNML
005 20130813105535.0
008 100122s2009 fr a b i||| | eng
020 $a9789264076792 (print)
020 $a9264076794 (print)
020 $a9789264076808 (PDF)
020 $a9264076808 (PDF)
035 $a(OCoLC)526792465
035 $a772142
040 $aDLC$beng$cDLC$dNOH$dTWTNM
050 00$aRM301.3.G45$bP433 2009
082 04$a615.19$223
245 00$aPharmacogenetics :$bopportunities and challenges for health innovation.
246 30$aOpportunities and challenges for health innovation
260 $aParis :$bOECD,$cc2009.
300 $a131 p. :$bill. ;$c23 cm.
490 1 $aOECD innovation strategy
500 $a"This work is published on the responsibility of the Secretary-General of the OECD"--T.p. verso.
500 $aCorrigenda to OECD publications may be found online at: www.oecd.org/publishing/corrigenda.
500 $aOECD-code: 93 2009 08 1 P.
504 $aIncludes bibliographical references.
505 2 $aIntroduction to the policy issues -- The supporting infrastructures for pharmacogenetics -- Pharmacogenetics and drug development -- Business models for pharmacogenetics -- Physician and patient demand for pharmacogenetics -- Regulatory authorities and reimbursement mechanisms -- Conclusions.
520 $aPharmacogenetics helps us understand the relationship between an individual's genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimize the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.--Publisher's description.
530 $aAlso available online.
650 0$aPharmacogenetics.
650 0$aPharmaceutical industry$xTechnological innovations.
650 2$aDrug Industry.
710 2 $aOrganisation for Economic Co-operation and Development.$bSecretary-General.
710 2 $aSourceOECD (Online service)
830 0$aOECD innovation strategy.